Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H19N5.ClH |
Molecular Weight | 365.859 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CC(C)=C(NC2=NC(NC3=CC=C(C=C3)C#N)=NC=C2)C(C)=C1
InChI
InChIKey=RHIYZDNOTUMYCA-UHFFFAOYSA-N
InChI=1S/C20H19N5.ClH/c1-13-10-14(2)19(15(3)11-13)24-18-8-9-22-20(25-18)23-17-6-4-16(12-21)5-7-17;/h4-11H,1-3H3,(H2,22,23,24,25);1H
DescriptionCurator's Comment: Description was created using several sources including: http://www.mtnstopshiv.org/news/studies/mtn020 | https://www.ncbi.nlm.nih.gov/pubmed/14693562 | https://clinicaltrials.gov/ct2/show/NCT02010593
Curator's Comment: Description was created using several sources including: http://www.mtnstopshiv.org/news/studies/mtn020 | https://www.ncbi.nlm.nih.gov/pubmed/14693562 | https://clinicaltrials.gov/ct2/show/NCT02010593
Dapivirine, an anti-retroviral (ARV)-based microbicide, is a substituted diaminopyrimidine (DAPY) derivative and a potent non-nucleoside reverse-transcriptase inhibitor (NNRTI) with antiviral activity against HIV-1. Dapivirine showed high activity against wild-type and mutant HIV in in virto HIV models inhibiting a broad panel of HIV-1 isolates from different classes, including a wide range of NNRTI-resistant isolates. Developed by Janssen Sciences (formerly Tibotec Pharmaceuticals), dapivirine was initially tested as an oral treatment for HIV in a number of Phase I/II clinical trials. In 2014 the International Partnership for Microbicides (IPM) began its work on the monthly dapivirine ring. Phase I/II clinical trials in Africa, Europe and the United States proved that dapivirine is safe and well-tolerated. Phase III long-term safety and efficacy studies of the monthly dapivirine ring as part of IPM's Dapivirine Ring Licensure Program confirmed that the monthly dapivirine ring can safely help prevent HIV infection in women. In 2016 the ASPIRE Study reported a 27 percent reduction in HIV-1 acquisition with a trend toward greater protection in women over age 21 and no significant protection for women under age 21.
Originator
Curator's Comment: In 2004, Tibotec granted International Partnership for Microbicides (IPM) a non-exclusive, royalty-free license to develop dapivirine as a microbicide for use in resource-poor countries. This agreement expanded in 2014, when Janssen granted IPM exclusive worldwide rights to dapivirine.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. | 2004 May 6 |
|
Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. | 2010 Oct 15 |
|
Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors. | 2011 Jan |
|
Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents. | 2012 Dec 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02010593
The dapivirine matrix vaginal ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix inserts once every 4 weeks in postmenopausal women over 12 weeks of product use.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14693562
A 24-h treatment with 100 nM TMC120-R147681 (dapivirine) prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV when studied using monocyte-derived dendritic cells (MO-DC) and autologous CD4+ T cells, representing early targets during sexual transmission.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000174409
Created by
admin on Sat Dec 16 00:41:45 GMT 2023 , Edited by admin on Sat Dec 16 00:41:45 GMT 2023
|
PRIMARY | |||
|
244768-47-6
Created by
admin on Sat Dec 16 00:41:45 GMT 2023 , Edited by admin on Sat Dec 16 00:41:45 GMT 2023
|
PRIMARY | |||
|
55D48BY90H
Created by
admin on Sat Dec 16 00:41:45 GMT 2023 , Edited by admin on Sat Dec 16 00:41:45 GMT 2023
|
PRIMARY | |||
|
DBSALT002396
Created by
admin on Sat Dec 16 00:41:45 GMT 2023 , Edited by admin on Sat Dec 16 00:41:45 GMT 2023
|
PRIMARY | |||
|
22398432
Created by
admin on Sat Dec 16 00:41:45 GMT 2023 , Edited by admin on Sat Dec 16 00:41:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD